

ASX Announcement

Racura Oncology Investor Briefings – Hong Kong and Singapore

3 March 2026 – Racura Oncology Limited (“Racura”) wishes to invite investors to attend briefings with CEO Dr Daniel Tillett and Executive Chair Dr Pete Smith in Hong Kong and Singapore, this April on the following dates:

- Lunch briefing with a presentation by Dr Pete Smith, Executive Chair of Racura in Hong Kong on Tuesday, 14 April 2026
- Lunch briefing with a presentation by Dr Daniel Tillett, CEO and Managing Director of Racura, together with Dr Nina Webster and Dr Rob Shepherd of Dimerix (ASX: DXB), in Singapore on Monday, 20 April 2026

Briefings will be held in central CBD locations as lunches, with the final venues and timing to be confirmed closer to the event date. These sessions will provide investors with an opportunity to meet and talk with Racura management, who will also provide an update on the company’s strategic and clinical development plans.

Interested parties are encouraged to RSVP by 20 March 2026 via: racura@irdepartment.com.au. Please indicate which city you are interested in attending the briefing and any dietary requirements.

The Racura team looks forward to meeting and discussing with investors the outlook and opportunities for the company.

-ENDS-

About Racura Oncology (ASX: RAC)

Racura Oncology (ASX: RAC) is a Phase 3 stage clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Racura's lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over (E,E)-bisantrene.

Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase 3 clinical program in acute myeloid leukaemia (AML), Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

Racura Oncology has collaborated with Astex, Emory University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.

If you have any questions on this announcement, or any past Racura Oncology announcements please visit our [Interactive Announcements](#) page.

Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Daniel Tillett, CEO
info@racuraoncology.com

Media contact:

Cherie Hartley +61 418 737 020
cherie.hartley@irdepartment.com.au